These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 18197434

  • 1. Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge.
    Sebban C, Dussart S, Fuhrmann C, Ghesquieres H, Rodrigues I, Geoffrois L, Devaux Y, Lancry L, Chvetzoff G, Bachelot T, Chelghoum M, Biron P.
    Support Care Cancer; 2008 Sep; 16(9):1017-23. PubMed ID: 18197434
    [Abstract] [Full Text] [Related]

  • 2. Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients.
    Rolston KV, Frisbee-Hume SE, Patel S, Manzullo EF, Benjamin RS.
    Support Care Cancer; 2010 Jan; 18(1):89-94. PubMed ID: 19387695
    [Abstract] [Full Text] [Related]

  • 3. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectious diseases group trial XV.
    Kern WV, Marchetti O, Drgona L, Akan H, Aoun M, Akova M, de Bock R, Paesmans M, Viscoli C, Calandra T.
    J Clin Oncol; 2013 Mar 20; 31(9):1149-56. PubMed ID: 23358983
    [Abstract] [Full Text] [Related]

  • 4. Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin.
    Chamilos G, Bamias A, Efstathiou E, Zorzou PM, Kastritis E, Kostis E, Papadimitriou C, Dimopoulos MA.
    Cancer; 2005 Jun 15; 103(12):2629-35. PubMed ID: 15856427
    [Abstract] [Full Text] [Related]

  • 5. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
    Innes H, Lim SL, Hall A, Chan SY, Bhalla N, Marshall E.
    Support Care Cancer; 2008 May 15; 16(5):485-91. PubMed ID: 17899215
    [Abstract] [Full Text] [Related]

  • 6. Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial.
    Petrilli AS, Dantas LS, Campos MC, Tanaka C, Ginani VC, Seber A.
    Med Pediatr Oncol; 2000 Feb 15; 34(2):87-91. PubMed ID: 10657866
    [Abstract] [Full Text] [Related]

  • 7. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, Le Berre MA, Lode H, Winter J, Read RC, MOTIV (MOxifloxacin Treatment IV) Study Group.
    Clin Infect Dis; 2008 May 15; 46(10):1499-509. PubMed ID: 18419482
    [Abstract] [Full Text] [Related]

  • 8. A randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired pneumonia.
    Höffken G, Barth J, Rubinstein E, Beckmann H, HAP study group.
    Infection; 2007 Dec 15; 35(6):414-20. PubMed ID: 18034211
    [Abstract] [Full Text] [Related]

  • 9. Single-agent, broad-spectrum fluoroquinolones for the outpatient treatment of low-risk febrile neutropenia.
    Cooper MR, Durand CR, Beaulac MT, Steinberg M.
    Ann Pharmacother; 2011 Sep 15; 45(9):1094-102. PubMed ID: 21862714
    [Abstract] [Full Text] [Related]

  • 10. Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment.
    Minotti V, Gentile G, Bucaneve G, Iori AP, Micozzi A, Cavicchi F, Barbabietola G, Landonio G, Menichetti F, Martino P, Del Favero A.
    Support Care Cancer; 1999 May 15; 7(3):134-9. PubMed ID: 10335931
    [Abstract] [Full Text] [Related]

  • 11. Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia.
    Paganini H, Rodriguez-Brieshcke T, Zubizarreta P, Latella A, Firpo V, Casimir L, Armada A, Fernández C, Cáceres E, Debbag R.
    Cancer; 2001 Apr 15; 91(8):1563-7. PubMed ID: 11301406
    [Abstract] [Full Text] [Related]

  • 12. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections.
    Solomkin J, Zhao YP, Ma EL, Chen MJ, Hampel B, DRAGON Study Team.
    Int J Antimicrob Agents; 2009 Nov 15; 34(5):439-45. PubMed ID: 19692210
    [Abstract] [Full Text] [Related]

  • 13. [Efficacy of moxifloxacin (Avelox) in prophylaxis of infection in patients with profound neutropenia].
    Minenko SV, Dmitrieva NV, Sokolova EN, Zhukov NV, Ptushkin VV.
    Antibiot Khimioter; 2004 Nov 15; 49(3):26-31. PubMed ID: 15344394
    [Abstract] [Full Text] [Related]

  • 14. Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia.
    Girmenia C, Russo E, Carmosino I, Breccia M, Dragoni F, Latagliata R, Mecarocci S, Morano SG, Stefanizzi C, Alimena G.
    Ann Hematol; 2007 Apr 15; 86(4):263-70. PubMed ID: 17225113
    [Abstract] [Full Text] [Related]

  • 15. Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study).
    Weiss G, Reimnitz P, Hampel B, Muehlhofer E, Lippert H, AIDA Study Group.
    J Chemother; 2009 Apr 15; 21(2):170-80. PubMed ID: 19423470
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens.
    Hoeffken G, Talan D, Larsen LS, Peloquin S, Choudhri SH, Haverstock D, Jackson P, Church D.
    Eur J Clin Microbiol Infect Dis; 2004 Oct 15; 23(10):772-5. PubMed ID: 15605184
    [Abstract] [Full Text] [Related]

  • 17. Outpatient treatment of neutropenic fever with oral antibiotics and granulocyte colony-stimulating factor.
    Papadimitris C, Dimopoulos MA, Kostis E, Papadimitriou C, Anagnostopoulos A, Alexopoulos G, Papamichael C, Gika D, Mitsibounas D, Stamatelopoulos S.
    Oncology; 1999 Oct 15; 57(2):127-30. PubMed ID: 10461059
    [Abstract] [Full Text] [Related]

  • 18. Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia.
    Gupta A, Swaroop C, Agarwala S, Pandey RM, Bakhshi S.
    J Pediatr Hematol Oncol; 2009 Sep 15; 31(9):635-41. PubMed ID: 19684522
    [Abstract] [Full Text] [Related]

  • 19. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease: a single-center, randomized, controlled trial in Argentina.
    Paganini H, Gómez S, Ruvinsky S, Zubizarreta P, Latella A, Fraquelli L, Iturres AS, Casimir L, Debbag R.
    Cancer; 2003 Apr 01; 97(7):1775-80. PubMed ID: 12655535
    [Abstract] [Full Text] [Related]

  • 20. Ceftriaxone monotherapy in the treatment of low-risk febrile neutropenia.
    Karthaus M, Wolf HH, Kämpfe D, Egerer G, Ritter J, Peters G, Südhoff T, Franke A, Heil G, Kullmann KH, Jürgens H.
    Chemotherapy; 1998 Apr 01; 44(5):343-54. PubMed ID: 9732151
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.